SARA MCCUTCHAN

Director of Regulatory Affairs and Quality Aristea Therapeutics

Sara McCutchan Director of Regulatory Affairs and Quality and a founding team member of Aristea Therapeutics. Aristea Therapeutics has raised $138 million and has a collaboration and option to acquire deal with Pfizer.

McCutchan is a distinguished life sciences expert in regulatory affairs and quality assurance who has obtained regulatory approvals to conduct clinical studies in three debilitating inflammatory diseases in seven countries. She also led a successful nonproprietary (generic) naming process with the World Health Organization (WHO) for Aristea’s lead drug candidate. Before Aristea, McCutchan played an integral role in the regulatory affairs function at Ardea Biosciences, supporting and managing marketing authorizations in the U.S., European Union, Latin America, Australia and New Zealand. At Ardea, she also spent several years in quality assurance, supporting three successful FDA inspections and managed internal quality systems and employee training.